Moderna works at a variant-specific booster dose

• Ema starts modern vaccine evaluation for age group 6-11

• Vaccines, Modern: Fda decision slide for use on teenagers

Share

November 26, 2021 The US pharmaceutical company Moderna wants to develop a specific booster dose for the so-called Omicron variant of Covid-19, which the WHO has defined as "worrying".

This was announced by the same pharmaceutical company in a note, explaining that one of the three 'strategic' corporate units will work towards the goal.

"Mutations in the Omicron variant are worrying and for several days we have been moving as fast as possible to implement our strategy to address this variant," said Stephane Bance, CEO of Moderna.